Following a hefty Series B, Silverback Therapeutics quickly pulls in $85M for 'an important growth phase'

Nicole DeFeudis

Editor

Months after reeling in a $78 million Series B round, Silverback Therapeutics has hooked an even larger Series C.

The Seattle-based company announced Wednesday that it netted $85 million from a slate of new and previous investors. The quick boost could be a sign that an IPO is on the way.

In an email, Silverback CEO Laura Shawver told me she was “not able to provide any additional comments about Silverback” beyond what was shared in the company’s news release. In the prepared statement, she said the company is at “an important growth phase.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER

Following a hefty Series B, Silverback Therapeutics quickly pulls in $85M for 'an important growth phase'

Nicole DeFeudis

Editor

Unlock this article instantly by becoming a free subscriber.

J&J’s challenge to AstraZeneca in lung cancer takes flight with PhIII PFS win

Federal government shutdown watch: FDA and industry prep for likely closure Oct. 1

FDA approves major depressive drug after rejecting it multiple times in past two decades

Stephen Hahn’s liquid biopsy company Harbinger Health raises $140M Series B to launch first cancer tests by 2025

How academic centers are trying to keep their promising drug discoveries out of the ‘valley of death’

5 Patient Engagement & Recruitment Trends, and How to Keep Up with Them

Fol­low­ing a hefty Se­ries B, Sil­ver­back Ther­a­peu­tics quick­ly pulls in $85M for 'an im­por­tant growth phase'

Nicole DeFeudis

Editor

Unlock this article instantly by becoming a free subscriber.

J&J’s chal­lenge to As­traZeneca in lung can­cer takes flight with PhI­II PFS win

Fed­er­al gov­ern­ment shut­down watch: FDA and in­dus­try prep for like­ly clo­sure Oct. 1

FDA ap­proves ma­jor de­pres­sive drug af­ter re­ject­ing it mul­ti­ple times in past two decades

Stephen Hahn’s liq­uid biop­sy com­pa­ny Har­bin­ger Health rais­es $140M Se­ries B to launch first can­cer tests by 2025

How aca­d­e­m­ic cen­ters are try­ing to keep their promis­ing drug dis­cov­er­ies out of the ‘val­ley of death’

5 Pa­tient En­gage­ment & Re­cruit­ment Trends, and How to Keep Up with Them

Following a hefty Series B, Silverback Therapeutics quickly pulls in $85M for 'an important growth phase'

J&J’s challenge to AstraZeneca in lung cancer takes flight with PhIII PFS win

Federal government shutdown watch: FDA and industry prep for likely closure Oct. 1

FDA approves major depressive drug after rejecting it multiple times in past two decades

Stephen Hahn’s liquid biopsy company Harbinger Health raises $140M Series B to launch first cancer tests by 2025

How academic centers are trying to keep their promising drug discoveries out of the ‘valley of death’

5 Patient Engagement & Recruitment Trends, and How to Keep Up with Them